How (CVRX) Movements Inform Risk Allocation Models
This article analyzes Cvrx Inc. (NASDAQ: CVRX) using AI models to inform risk allocation. It highlights a prevailing positive sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup. The analysis provides specific trading strategies—Position, Momentum Breakout, and Risk Hedging—alongside multi-timeframe signal analysis, including support and resistance levels for various time horizons.
CVRx touts Barostim therapy as improving exercise capacity in heart failure beyond GDMT alone
CVRx is promoting its Barostim device at ACC26, highlighting its ability to improve exercise capacity and quality of life for heart failure patients for whom standard medical therapy is insufficient. The Barostim system works by targeting the neurohormonal pathway and is presented as a new treatment option. The company recently completed its first Barostim implant at Orlando Health South Lake Hospital and presented promising real-world data at THT2026.
SGP,CVRX Volatility & Greeks
This article provides detailed financial data, analyst ratings, and insider transaction information for two companies: SpyGlass Pharma Inc (SGP) and CVRx Inc (CVRX). It highlights recent stock performance, key financial metrics, news events, and insider trading activities for both healthcare companies.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CVRx, Inc. (CVRX) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential claims against CVRx, Inc. (NASDAQ:CVRX) following several drops in its stock price. The investigation focuses on alleged missteps related to sales force changes and their impact on revenue guidance and growth. Shareholders who purchased CVRx securities are encouraged to contact the firm to assist in the investigation.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into CVRx, Inc. (CVRX) following significant drops in the company's stock price after several disappointing financial announcements. The investigation focuses on potential claims for purchasers of CVRx securities, encouraging affected shareholders to learn more and assist the firm. The stock price declines followed reports of lower-than-anticipated revenue and the impact of sales force changes.
CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. (NASDAQ: CVRX) securities. The investigation follows several drops in CVRx's stock price after the company reported disappointing financial results and revised guidance, attributing issues to sales force changes and integration challenges. Shareholders are encouraged to contact the firm to learn more about participating in the investigation.
CVRx, Inc. (NASDAQ:CVRX) Q4 2025 earnings call transcript
This article provides the Q4 2025 earnings call transcript for CVRx, Inc. (NASDAQ:CVRX). It details the financial discussions and corporate updates presented during the call.
Bronstein, Gewirtz & Grossman, LLC Is Investigating CVRx, Inc. (CVRX) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. (NASDAQ: CVRX) securities. The investigation follows multiple drops in CVRx's stock price after the company announced lower than anticipated revenues, slashed full-year guidance, and reported significant impacts from sales organization changes. Investors are encouraged to contact the firm for more information and to assist with the investigation.
Bronstein, Gewirtz & Grossman, LLC Encourages CVRx, Inc. (CVRX) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims on behalf of purchasers of CVRx, Inc. (NASDAQ: CVRX) after the company's stock price dropped following several disappointing revenue announcements and revised guidance. The firm encourages CVRx stockholders to visit their website or contact them directly to assist with the investigation, emphasizing that their representation is on a contingency fee basis with no upfront cost to investors.
CVRx Inc Stock (ISIN: US12674F1003) Gains Momentum on Heart Failure Device Adoption Amid Medtech Sec
CVRx Inc (ISIN: US12674F1003) is gaining investor interest due to the growing adoption of its Barostim therapy for heart failure patients. The Barostim system, which improves cardiac function through neuromodulation, is seeing positive real-world evidence and expanding commercialization. This development is particularly relevant for European investors considering the significant prevalence of heart failure in the region and the potential for regulatory alignment and market expansion.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against CVRx, Inc. (CVRX) on behalf of investors. The investigation stems from multiple drops in CVRx's stock price following announcements of lower-than-anticipated revenues and significant impacts from sales force changes in April 2025, May 2025, and February 2026. The firm encourages affected investors to learn more and assist the investigation.
CVRx, Inc. (NASDAQ:CVRX) Q4 2025 earnings call transcript
This is the Q4 2025 earnings call transcript for CVRx, Inc. (NASDAQ:CVRX). The transcript details the company's financial results and discussions from the call.
Trading Systems Reacting to (CVRX) Volatility
This article analyzes Cvrx Inc. (NASDAQ: CVRX) volatility, highlighting positive sentiment and a mid-channel oscillation pattern. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—alongside multi-timeframe signal analysis to guide investors. The analysis indicates a strong near-term and mid-term outlook, with a neutral long-term signal, and an exceptional risk-reward setup targeting a 29.4% gain.
Bronstein, Gewirtz & Grossman, LLC Is Investigating CVRx, Inc. (CVRX) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against CVRx, Inc. (CVRX) on behalf of investors who purchased the company's securities. The investigation follows multiple drops in CVRx's stock price after the company reported lower-than-anticipated revenues, revised its full-year guidance downwards, and acknowledged significant negative impacts from Salesforce changes and sales organization cuts. The law firm is encouraging affected stockholders to connect to assist with the investigation.
FinancialContent - CVRx, Inc. (CVRX) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
The Law Offices of Howard G. Smith are investigating CVRx, Inc. (CVRX) on behalf of investors who suffered losses due to potential violations of federal securities laws. The investigation stems from significant stock declines after CVRx announced disappointing quarterly results, reduced full-year revenue guidance, and reported ongoing challenges with its sales representatives in April 2025, May 2025, and February 2026. Investors are encouraged to contact the firm to discuss their legal rights and potential claims.
CVRx (CVRX) CMO granted 62K options, 41K RSUs and sells 1.3K shares
CVRx, Inc. Chief Medical Officer Philip B. Adamson was granted 62,000 stock options and 41,000 restricted stock units (RSUs) on February 27, 2026. Concurrently, he sold 1,262 shares on March 2, 2026, at an average price of $7.90 per share, to satisfy tax withholding obligations. Following these transactions, Adamson directly owns 61,578 common shares of CVRx.
First Barostim procedure at Ascension Alexian Brothers backed by CVRx
CVRx supported the first Barostim implant at Ascension Alexian Brothers, a significant step in providing advanced device therapy for heart failure patients. This procedure, performed by Dr. Georges Haidar, Dr. Ashish Haryani, and Dr. Baqir Lakhani, expands access to a novel treatment. CVRx continues its efforts to develop medical treatments through collaborations, building on previous successes like the 101st Barostim implant.
IMA,CVRX Volatility & Greeks
This article provides detailed financial data and recent news for two biotechnology companies, ImageneBio Inc. (IMA) and CVRx Inc. (CVRX). It includes stock performance metrics, insider trading activities, analyst ratings, and press release headlines for both companies, offering a comprehensive overview of their current market standing and recent developments.
IMA,CVRX Options
This article provides detailed financial data, analyst ratings, and insider trading information for two biotechnology companies: ImageneBio Inc (IMA) and CVRx Inc (CVRX). It includes their latest stock performance, market capitalization, earnings per share, sales figures, and recent news announcements, offering a comprehensive snapshot of their current market positions and recent activities.
CVRX Earning Date, Earning Analysis and Earning Prediction
This article provides an earnings analysis and prediction for CVRX, detailing past quarterly results, future forecasts, and stock price reactions. It highlights analyst estimates for 2026/Q1, with projected revenue of $14.38M and an EPS of -$0.50, and discusses the correlation between earnings forecast revisions and stock price movements. The piece also summarizes the positive sentiment from the Q4 2025 earnings call, anticipating a potential stock price increase of 2% to 8%.
CVRX SEC Filings - Cvrx, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for CVRx, Inc. (NASDAQ: CVRX) SEC filings, including annual 10-K reports, quarterly 10-Q reports, and 8-K forms detailing material events. It highlights the company's focus on neuromodulation solutions for cardiovascular diseases, particularly its Barostim platform, and offers AI-powered summaries of these regulatory documents. Recent filings discuss Q3 2025 financial results, the finalization of new CPT codes for Barostim, and equity awards for the company's COO.
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
CVRx, Inc. (NASDAQ:CVRX) has received a consensus "Moderate Buy" recommendation from brokerages, with an average one-year target price of $11.20. Despite missing Q4 EPS estimates with ($0.46) per share, the company's revenue of $16.02 million slightly exceeded expectations. Insider activity includes Director Mudit K. Jain purchasing 46,800 shares, increasing his stake and highlighting continued insider and institutional interest.
How Cvrx Inc. (CVRX) Affects Rotational Strategy Timing
This article analyzes CVRX's impact on rotational strategy timing, highlighting strong near and mid-term sentiment but a weak long-term outlook. It identifies an exceptional risk-reward setup with a potential 32.4% gain and outlines three institutional trading strategies tailored for different risk profiles. The analysis includes multi-timeframe signal analysis and details for position, momentum breakout, and risk hedging strategies.
CVRx Introduces New Performance-Based Executive Stock Unit Plan
CVRx (CVRX) has introduced a new performance-based executive stock unit plan, approved by its board compensation committee on February 27, 2026. This plan ties executive incentives to a cumulative revenue goal for the 2026-2027 fiscal performance period, with payouts ranging from 50% to 200% based on performance. The initiative aims to strengthen management retention, drive significant revenue growth, and align executive interests with those of shareholders during a crucial growth phase for the medical technology company.
CVRx Introduces New Performance-Based Executive Stock Unit Plan
CVRx Inc. has introduced a new performance-based executive stock unit plan, approved by its board compensation committee, to incentivize executive officers. The plan is tied to a cumulative revenue goal for the 2026-2027 fiscal period, with payouts ranging from 50% to 200% of the target based on performance and vesting through December 2028. This move aims to strengthen management retention and align executive incentives with shareholder interests during a critical growth phase for the medical technology company.
CVRx (CVRX) lists Chief HR Officer Gregory Morrison as insider on Form 3
CVRx, Inc. has filed a Form 3, an initial statement of beneficial ownership, for Gregory Morrison, who serves as the Chief Human Resources Officer. This filing establishes Morrison's status as an insider, and discloses his equity holdings, though no securities are currently beneficially owned. The Form 3 is critical for future transparency regarding his transactions as an insider.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
Pomerantz LLP is investigating potential securities fraud claims against CVRx, Inc. (CVRX) following significant drops in its stock price. The investigation focuses on whether the company misled investors regarding weaker-than-expected Q1 2025 preliminary and final results, attributing poor performance to new sales representatives being in early development stages and significant salesforce changes. These announcements led to stock price declines of 46.3% and 38.7% respectively.
CVRX Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Cvrx, Inc. (CVRX) for fiscal year 2025, including income statement, balance sheet, and cash flow data, alongside key financial ratios and health scores. It highlights the company's revenue growth, strong liquidity and return on equity despite negative profitability, cash flow, and debt servicing concerns. The analysis also covers the Piotroski F-Score, earnings quality, and cash runway, concluding with an overall moderate financial health assessment.
CVRx (CVRX) CEO Kevin Hykes gets major equity grants, sells shares for taxes
CVRx, Inc. CEO Kevin Hykes received substantial equity grants, including 238,000 stock options and 159,000 restricted shares, which will vest over several years. To cover tax withholding obligations associated with these awards, he sold 7,763 common shares at a weighted average price of $7.9027 per share in a required "sell-to-cover" transaction. Following these transactions, Hykes directly owned 284,237 common shares of CVRx.
CVRx (NASDAQ: CVRX) officer receives major equity grants, sells shares to cover taxes
CVRx, Inc.’s Chief Marketing and Strategy Officer, Paul Verrastro, received significant equity grants including 45,000 restricted stock units and stock options for 67,000 shares on February 27, 2026. Shortly after, on March 2, 2026, Verrastro sold 1,284 common shares at a weighted average price of $7.9021 to cover tax withholding obligations. Following these transactions, he directly holds 60,551 common shares and 67,000 stock options.
CVRx (NASDAQ: CVRX) CFO gets major option, RSU grants and tax sale
CVRx, Inc.'s CFO, Jared Oasheim, reported significant equity grants, including 91,000 stock options and 61,000 restricted stock units, with specified vesting schedules. To cover tax withholding obligations from these awards, he conducted a mandated sell-to-cover transaction, selling 1,744 shares of common stock at a weighted-average price of $7.9022 per share. Following these transactions, Oasheim directly holds 96,703 shares of CVRx common stock.
CVRx (NASDAQ: CVRX) CRO gets new stock awards, sells shares for taxes
CVRx, Inc.'s Chief Revenue Officer, John Robert Allen, reported receiving new equity awards consisting of 35,000 restricted stock units and 52,000 stock options, both with multi-year vesting schedules starting in 2027. Concurrently, he sold 3,964 shares of common stock at a weighted average price of $7.9025 per share to cover tax withholding obligations associated with equity awards. This transaction is characterized as a routine tax-related sale rather than a discretionary reduction in his holdings, increasing his long-term equity exposure to the company.
CVRX,INVA Dividends
This article provides detailed financial and news summaries for CVRx Inc (CVRX) and Innoviva Inc (INVA). It includes stock performance metrics, analyst ratings, recent news releases, and insider trading activity for both companies. The data highlights their market positions within the healthcare sector, focusing on medical devices for CVRx and biotechnology for Innoviva.
AI Investing Insights - Official Homepage - Intellectia AI™
This page from Intellectia AI presents a detailed cash flow statement for CVRX, including quarterly data from FY2021Q1 to FY2025Q4. It breaks down various cash flow components such as operating activities, investing activities, financing activities, and free cash flow, alongside year-over-year percentage changes. The platform positions itself as a trusted AI platform for winning trades, offering various tools and resources related to AI investing.
CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
CVRx, Inc. announced its schedule of scientific presentations for the Technology and Heart Failure Therapeutics 2026 (THT) meeting, highlighting new data on its Barostim therapy. Presentations will include six-month outcomes from the REBALANCE Registry and insights into Barostim's impact on hospitalizations, LVEF, and cardiac hemodynamics. The company will also host a satellite program to discuss ongoing trials like BREATHE-HF and the newly initiated BENEFIT-HF, which aims to expand Barostim's use in a wider heart failure population.
CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
CVRx announced the schedule of scientific presentations for its Barostim therapy at the THT 2026 annual meeting in Boston. The presentations will feature late-breaking REBALANCE Registry data, discussing six-month outcomes in over 400 patients, as well as scientific sessions covering real-world outcomes, cardiac energetics, and the impact of Barostim on hospitalizations and LVEF improvements. CVRx will also host a satellite program providing updates on ongoing trials like REBALANCE, BREATHE-HF, and the newly initiated BENEFIT-HF trial.
CVRX Stock News Today | Earnings, Events & Price Alerts
This article provides recent news and event updates for CVRx (CVRX). Key information includes the unveiling of new data on Barostim therapy, several investigations by Pomerantz LLP for securities fraud, and announcements regarding CVRx's Q4 revenue and FY26 gross margin and operating expense outlook. The CEO highlighted strong support at high-potential centers, new CPT codes, and the initiation of the BENEFIT-HF trial as drivers for accelerated growth.
SGP,CVRX Short Interest
This article provides detailed financial data, analyst ratings, and insider trading information for two biotechnology companies, SpyGlass Pharma Inc (SGP) and CVRx Inc (CVRX). It highlights recent stock performance, key financial metrics, and a history of news and analyst actions for both companies.
IMA,CVRX Earnings
This article provides detailed financial data and news updates for two biotechnology companies: ImageneBio Inc (IMA) and CVRx Inc (CVRX). It includes stock performance metrics, insider trading information, analyst ratings, and recent corporate announcements for both companies. The content offers a snapshot of their market positions, financial health, and key developments.
IMA,CVRX Dividends
This article provides detailed financial data, recent news, and insider trading information for ImageneBio Inc (IMA) and CVRx Inc (CVRX). It covers stock performance metrics, analyst ratings, and company-specific news releases, offering a comprehensive snapshot of each company's financial health and market activity.
SGP,CVRX Earnings
This article provides detailed financial and operational data for SpyGlass Pharma Inc. (SGP) and CVRx Inc. (CVRX), including stock performance, market capitalization, insider ownership, and recent news. It highlights SGP's focus on developing treatments for chronic eye conditions and CVRX's neuromodulation solutions for cardiovascular diseases, along with their latest earnings reports and analyst ratings.
CVRx partners with Orlando Health South Lake Hospital for first Barostim implant
CVRx announced a new partnership with Orlando Health South Lake Hospital to perform the hospital's first Barostim implant procedure. This collaboration, involving Dr. Ifran Imami and Dr. Roger Moccia, aims to improve outcomes and quality of life for heart failure patients. CVRx commended the hospital's dedication to advancing cardiovascular care through this initiative.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
Pomerantz LLP is investigating CVRx, Inc. (NASDAQ: CVRX) on behalf of investors for potential securities fraud and unlawful business practices. This investigation follows significant drops in CVRx's stock price after the company announced weaker-than-expected preliminary first-quarter results and subsequently lowered its full-year revenue guidance, attributing the poor performance to an inexperienced salesforce. Investors are encouraged to contact Pomerantz LLP for information on joining a potential class action.
AI Investing Insights - Official Homepage - Intellectia AI™
This page from Intellectia AI provides a detailed financial analysis of CVRX, presenting various key indicators, valuation ratios, profitability ratios, financial health ratios, efficiency ratios, and growth ratios. It shows historical quarterly data spanning several years, with percentage changes quarter-over-quarter. The data covers metrics such as PS, PB, Dividend Yield, FCF Yield, Gross Profit Margin, EBITDA Margin, Operating Margin, FCF Margin, Net Margin, Current Ratio, Quick Ratio, Debt to Equity, Interest Coverage Ratio, ROE, ROA, Average Inventory Days, Inventory Turnover, Average Receivables Collection Days, Accounts Receivable Turnover, Payables Turnover, and R&D % of Revenue, as well as YoY percentage changes for Total Revenue, EBITDA, and EPS.
(CVRX) and the Role of Price-Sensitive Allocations
This article analyzes Cvrx Inc. (NASDAQ: CVRX), highlighting a near-term strong sentiment challenging persistent mid and long-term weakness. It identifies a significant risk-reward short setup and outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also provides multi-timeframe signal strengths and support/resistance levels.
$CVRX stock is up 9% today. Here's what we see in our data.
CVRX stock has risen 9% today with $3.7 million in trading volume, making it the 505th most-searched ticker on Quiver Quantitative. Insider trading data shows 8 transactions in the past 6 months, with 2 purchases and 6 sales. Hedge fund activity reveals 37 institutional investors increasing their positions and 54 decreasing them in the last quarter, while analysts have issued 1 buy rating and a median price target of $11.5 from two analysts.
Director-linked Treo Ventures buys 46,800 CVRx (CVRX) shares
Treo Ventures I, L.P., an entity linked to CVRx director Mudit K. Jain, purchased 46,800 shares of CVRx common stock on February 20, 2026. The shares were bought in open-market transactions at a weighted average price of $6.3588 per share. After this transaction, Jain directly holds 5,650 common shares, with Treo Ventures I, L.P. holding an additional 980,183 shares.
CVRx director Jain Mudit K. buys $297k in shares By Investing.com
CVRx director Jain Mudit K. recently purchased 46,800 shares of common stock for a total of $297,591 on February 20, 2026. This transaction comes amidst a 23% surge in the company's stock value over the past week. The director now directly holds 5,650 shares and indirectly 980,183 shares through Treo Ventures I, L.P. The company also reported a slight miss on fourth-quarter 2025 EPS but exceeded revenue expectations, with Canaccord Genuity maintaining a Buy rating but lowering the stock price target.
Insider Purchase: Director at $CVRX Buys 46,800 Shares
A director at CVRX, Mudit K. Jain, recently purchased 46,800 shares of the company's stock for an estimated $297,591, increasing his holdings by 5.0%. This transaction is part of broader insider trading activity, which includes 2 purchases and 6 sales in the past six months, and significant adjustments in institutional holdings with 36 investors adding and 54 decreasing their positions. Analysts maintain a "Buy" rating on CVRX, with price targets ranging from $10.0 to $13.0.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
Pomerantz LLP is investigating potential securities fraud claims against CVRx, Inc. (NASDAQ: CVRX) on behalf of its investors. The investigation follows two significant stock price drops in 2025 after the company announced weaker-than-expected quarterly results and lowered its revenue guidance due to salesforce issues. Investors affected by these events are encouraged to contact the law firm.
